Clinical trials: Prostate Cancer, Castration Resistant
Metastatic Prostate Cancer, Bone Metastasis
Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPC
Bone is the most common site of metastases in prostate cancer and bone complications cause substantial morbidity to this population.
- Trial name
- SubDueP (NCT01062503)
- Testing
- Zoledronic acid
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer, Castration Resistant Prostate Cancer
Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
This study was conducted in subjects in chemotherapy-naïve subjects with bone-metastatic castration-resistant prostate cancer (CRPC).
- Conditions
- Prostate Cancer, Castration Resistant Prostate Cancer, Prostatic Neoplasms
- Trial name
- NCT01995058
- Testing
- cabozantinib, abiraterone, prednisone
- Where
- 20 sites in United States
- Volunteers
- 54 people
- Sponsor
- Exelixis
Prostate Cancer Metastatic
A Phase I/II Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)
This phase I/IIa study is a multi-center, prospective, open-label study evaluating safety and biological efficacy of up to six dose levels of Osteodex of patients with metastatic castration resistant prostate cancer (CRPC).
- Trial name
- NCT01595087
- Testing
- Osteodex
- Where
- 3 sites in Sweden
- Volunteers
- 28 people
- Sponsor
- DexTech Medical AB
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer
CD46 is an exciting new therapeutic target in prostate cancer, with the antibody drug conjugate FOR46 under investigation in phase I clinical trials.
- Trial name
- NCT05245006
- Testing
- 89Zr-DFO-YS5, YS5 antibody, Positron Emission Tomography (PET)/Computerized tomography (CT)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Robert Flavell, MD, PhD
Metastatic Castration-Resistant Prostate Cancer
A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy
The purpose of this study is to evaluate the percentage of participants achieving prostate-specific antigen (PSA) response by 12 weeks of therapy from baseline according to Prostate Cancer Clinical Trials Working Group (PCWG2)…
- Trial name
- NCT02405858
- Testing
- Abiraterone Acetate, Prednisolone
- Where
- 14 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Janssen Pharmaceutical K.K.
Prostate Neoplasms
A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to collect additional safety data during treatment with abiraterone acetate plus prednisone or prednisolone among adult participants with asymptomatic or mildly symptomatic metastatic…
- Trial name
- NCT01834209
- Testing
- Abiraterone acetate, Prednisone or prednisolone
- Where
- 8 sites in Brazil
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer
A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy
This research is being done to test an investigational drug, called itraconazole, in the treatment of prostate cancer. Itraconazole is approved by the Food and Drug Administration (FDA) for the treatment of various fungal…
- Trial name
- NCT00887458
- Testing
- Itraconazole 200 mg, Itraconazole 300mg
- Where
- 4 sites in United States
- Volunteers
- 46 people
- Sponsor
- Johns Hopkins University
Prostate Cancer
Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP)
This is a multicenter, Phase II randomized biomarker-based therapeutic study in metastatic prostate cancer experiencing prostate specific antigen (PSA) only progression (without visceral, bone or lymph node progression) while on…
- Trial name
- NCT05705700
- Testing
- Dutasteride, Abiraterone
- Sponsor
- Masonic Cancer Center, University of Minnesota
Metastatic Castration-resistant Prostate Cancer
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets
This study is conducted to investigate the pharmacokinetic and safety profiles of TQB3720 in patients with metastatic castration-resistant prostate cancer.
- Trial name
- NCT04853498
- Testing
- TQB3720
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer
This pilot clinical trial studies how well gallium Ga 68-DOTATATE positron emission tomography (PET)/computed tomography (CT) works in treating patients with castration resistant prostate cancer that has spread to other placed in…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7
- Trial name
- NCT03448458
- Testing
- CT (Computed Tomography), Gallium Ga 68-DOTATATE, Positron Emission Tomography
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Emory University
Solid Tumor, Solid Carcinoma
Imaging of Solid Tumors Using 18F-TRX
This phase I trial tests the safety and effectiveness of 18F-TRX in detecting tumors (cancer) patients with solid tumors. 18F-TRX is an imaging tracer that is used to visualize tumors using a PET scan.
- Conditions
- Solid Tumor, Solid Carcinoma, Castration-Resistant Prostate Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma
- Trial name
- NCT06942104
- Testing
- 18F-TRX, Positron Emission Tomography (PET)/Computerized tomography (CT), Tumor Biopsy
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Rahul Aggarwal
NSCLC Harboring NRG1 Fusion, Metastatic Castration-resistant Prostate Cancer
Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers
This is a Phase II, open-label, 2-arm, multicenter, international study designed to evaluate the efficacy of zenocutuzumab alone or in combination in patients with the following diagnoses: Group A: NRG1+ NSCLC Group B: mCRPC
- Trial name
- NCT05588609
- Testing
- Afatinib Oral Tablet, Enzalutamide Pill, Abiraterone acetate tablets
- Where
- 7 sites in United States
- Volunteers
- 13 people
- Sponsor
- Partner Therapeutics, Inc.
Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Urothelial Carcinoma
INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers
The purpose of this study is to plan for future clinical trials in patients with metastatic urological cancers. Diluted iodinated contrast will be injected intra-tumorally under CT fluoroscopy guidance into bone, lymph node, soft…
- Conditions
- Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Urothelial Carcinoma, Metastatic Renal Cell Carcinoma
- Trial name
- NCT03071328
- Testing
- Isovue-M 200
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Duke University
Prostate Cancer
A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC
The purpose of this study is to evaluate safety and tolerability, pharmacokinetics （PK）, efficacy of TRC003 injection in patients with progressive PSMA-positive mCRPC who have been treated with androgen receptor pathway inhibitor…
- Trial name
- NCT07567521
- Testing
- Radiopharmaceuticals
- Where
- 2 sites in China
- Volunteers
- 90 people
- Sponsor
- C Ray Therapeutics
Prostatic Neoplasms, Castration-Resistant
Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to determine what effects (good and bad) Enzalutamide and TVB-2640 have in the treatment of prostate cancer whose prostate cancer has spread to other parts of their body and that has not gotten better…
- Trial name
- NCT05743621
- Testing
- TVB-2640, Enzalutamide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC
This is a Phase Ib/II open label clinical trial in patients with metastatic castration resistant prostate cancer. The objective of the phase Ib portion of the study is to establish the maximum tolerated dose (MTD) and dose…
- Trial name
- NCT02494921
- Testing
- Docetaxel-PNP, Ribociclib, Prednisone
- Where
- 6 sites in United States
- Volunteers
- 43 people
- Sponsor
- Rahul Aggarwal
Prostate Cancer
Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer
The goal of this clinical study is to determine the safety and efficacy of VT-464, a lyase-selective inhibitor of CYP17, in patients with castration-resistant prostate cancer (CRPC) who have been previously treated with…
- Trial name
- NCT02130700
- Testing
- VT-464: given orally twice daily in 28-day cycles, VT-464: given orally once daily in 28-day cycles
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Innocrin Pharmaceutical
Metastatic Castration-resistant Prostate Cancer
Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of TABP EIC in patients with Metastatic castration-resistant prostate cancer.
- Trial name
- NCT03692663
- Testing
- TABP EIC, Cyclophosphamide, fludarabine
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Allife Medical Science and Technology Co., Ltd.
Metastatic Castration-resistant Prostate Cancer
Total Body PET-CT Imaging of Prostate Cancer Using Illuccix
Illuccix will be used per the prescribing instructions for PET-CT imaging on the United Imaging scanner uEXPLORER to establish a standard scanning protocol.
- Trial name
- NCT05558956
- Testing
- illuccix 68Ga-PSMA-11 Total Body PET-CT
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- BAMF Health
Prostate Cancer Metastatic
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall…
- Trial name
- OMAHA-003 (NCT06136624)
- Testing
- Opevesostat, Abiraterone acetate, Enzalutamide
- Where
- 288 sites in United States, Argentina and 34 more
- Volunteers
- 1,310 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.